First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - ScienceDirect

Figure 1 from Molecular Pathways: Fatty Acid Synthase

First-in-human study of the safety, pharmacokinetics, and

Emerging roles of fatty acid metabolism in cancer and their

Emerging roles of fatty acid metabolism in cancer and their

PDF) Metabolic dysregulation and emerging therapeutical targets

FASN inhibitor TVB-3166 prevents S-acylation of the spike protein

Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP

Acetyl-CoA metabolism as a therapeutic target for cancer

Frontiers First-In-Human Study to Assess the Safety

The role of lipids in cancer progression and metastasis

Acetyl-CoA metabolism as a therapeutic target for cancer

Fatty acids in cancer chemoresistance - ScienceDirect

PDF) Metabolic dysregulation and emerging therapeutical targets

First-in-human study of the safety, pharmacokinetics, and

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic